All News
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.
Read Article
Dr @ZahiTouma discusses the attribution rules for the NPSLE syndromes
Attribute to #SLE if
- onset of NP is near the SLE dx
- absence of concurrent nonSLE factors
- ⬇️ frequency of NP events in the gen pop'n
- diagnostic tools favor NPSLE
@RheumNow #ACR24 https://t.co/e1xBK4Xzsw
sheila RHEUMarampa ( View Tweet)
Very informative slide describing the 2 NPSLE pathogenetic pathways & their differences in mediators, mechanisms and NP events.
@RheumNow #ACR24
@rheumarhyme @theactiverheum https://t.co/D3XFDqxMBq
sheila RHEUMarampa ( View Tweet)
Walsh et al. Direct mailing of PEST questionnaire to psoriasis patients. 13% PEST+, 4% seen by rheum (to date). 75% deemed appropriate for rheum to see - breakdown in picture. @RheumNow #ACR24 Abstr#2635 https://t.co/vlGJ977SV7 https://t.co/dbDUpwDZxy
Links:
Richard Conway RichardPAConway ( View Tweet)
Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf
Links:
Richard Conway RichardPAConway ( View Tweet)
A#2647
DADA2 cohort 101 pts in India
Median delay dx 5 years - 5 pts of >20 yr
- 39 pts w GI involvement- bad outcomes
Skin most common - largely livedo, then ulcers/nodules
CNS common w ischemia
Many Rx before dx
12 deaths (11.8%) - 8 GI, 3 CVA, 1 suicide
#ACR24 @RheumNow https://t.co/Q8kiVbJq8I
Links:
Eric Dein ericdeinmd ( View Tweet)
A call to action in diagnosing and treating NPSLE 👇
Wonderful talks by Dr @ZahiTouma Dr. Betty Diamond and Dr. Susanne Benseler
@Rheumnow #ACR24 #lupus https://t.co/046ArRMP1a
sheila RHEUMarampa ( View Tweet)
Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs
Links:
Richard Conway RichardPAConway ( View Tweet)
SmPCs recommend interrupting immunosuppression (IS) in infection
What happens if you continue the drug?
Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection
Could continuation be a safe option in some pts?
#ACR24 @RheumNow https://t.co/14SN6a4Wm8
Mrinalini Dey DrMiniDey ( View Tweet)
RIP to Glucocorticoids in GPA
For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA).
https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0
Dr. John Cush RheumNow ( View Tweet)
Evaluation of Bimekizumab in PsA
At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
Study on #SLE and ESRD using machine learning:
Developed model to identify patients with SLE and ESRD
Used NIH 'All of Us' dataset
XGBoost outperformed Random Forest
SDOH data improved model precision #ACR24 @rheumnow #MachineLearning abst#1876 https://t.co/PQ7u4Pj5OH
Bella Mehta bella_mehta ( View Tweet)
Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV
Links:
Richard Conway RichardPAConway ( View Tweet)
@RheumNow interview at #ACR24 with Dr Harry Hurley about A#1694
Should we do one or two lungs when transplanting for autoimmune related ILD?
https://t.co/2omSSAPvgi https://t.co/BlAQjuBRFt
Links:
Eric Dein ericdeinmd ( View Tweet)
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Links:
Richard Conway RichardPAConway ( View Tweet)
How Online Searches Reveal Patient Needs
In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24
https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE
Dr. John Cush RheumNow ( View Tweet)
A#2363
Deodhar
Bimekizumab fast time to work:
BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose.
@RheumNow #ACR24 https://t.co/T81Lzyoy7m
Eric Dein ericdeinmd ( View Tweet)
Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
Links:
Richard Conway RichardPAConway ( View Tweet)
Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it.
@rheumnow abst#2160 #ACR24
Bella Mehta bella_mehta ( View Tweet)